Enveric Biosciences (ENVB) Research & Development (2016 - 2026)
Enveric Biosciences (ENVB) posted Research & Development of $345969.0 for Q1 2026, down 7.04% sequentially from $372178.0 in Q4 2025, and down 53.65% YoY from $746371.0 in Q1 2025.
Enveric Biosciences (ENVB) Research & Development (2016 - 2026) Analysis & Trends
Enveric Biosciences has reported Research & Development for 9 years, with the latest figure at $345969.0 in Q1 2026.
- Quarterly Research & Development fell 53.65% year-over-year to $345969.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 22.74% YoY) and the FY2025 annual result came in at $2.8 million, down 2.12% from the prior year.
- Research & Development slipped to $345969.0 in Q1 2026 per ENVB's latest filing, from $372178.0 in the prior quarter.
- Over five years, Research & Development peaked at $2.4 million in Q2 2023 and troughed at $345969.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $1.3 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 1140.07% in 2022, then sank 76.41% in 2024.
- Over 5 years, Research & Development stood at $1.9 million in 2022, then decreased by 9.1% to $1.7 million in 2023, then plunged by 43.79% to $967399.0 in 2024, then slumped by 61.53% to $372178.0 in 2025, then slipped by 7.04% to $345969.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $345969.0, $372178.0, and $402417.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 97.90 Mn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 345,969.00 |
| Dec 31, 2025 | 372,178.00 |
| Sep 30, 2025 | 402,417.00 |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 746,371.00 |
| Dec 31, 2024 | 967,399.00 |
| Sep 30, 2024 | 802,717.00 |
| Jun 30, 2024 | 565,001.00 |
| Mar 31, 2024 | 506,155.00 |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 2.40 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 1.96 Mn |
| Dec 31, 2021 | 2.49 Mn |
| Sep 30, 2021 | 1.22 Mn |
| Jun 30, 2021 | 879,843.00 |